Sandwich ELISA, Biotin-labelled antibody
Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate
At ambient temperature. Upon receipt, store the product at the temperature recommended below.
Store the kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Limit of Detection
n = 8; CV = 2.3%
n = 8; CV = 6.4%
- bovine Not tested
- cat Not tested
- dog Not tested
- goat Not tested
- hamster Not tested
- horse Not tested
- chicken Not tested
- monkey Not tested
- mouse Not tested
- pig Not tested
- rabbit Not tested
- rat Not tested
- sheep Not tested
- human Yes
- It is intended for research use only.
- The total assay time is less than 4 hours.
- The kit measures prouroguanylin in serum, plasma (EDTA, citrate, heparin).
- Assay format is 96 wells.
- Quality Controls are human serum based.
- No animal sera are used.
- Standard is recombinant protein based.
- Components of the kit are provided ready to use, concentrated or lyophilized.
Oncology, Others, Renal disease
Prouroguanylin (about 9,7 kDa) is a biologically inactive form of uroguanylin circulating in a bloodstream. Uroguanylin is a small –molecular-weight peptide which has been shown to participate in the regulation of salt and water homeostasis in mammals via cGMP-mediated processes in the intestine, kidney and other epithelia.
Prouroguanylin levels are markedly increased in chronic renal failure. The severity of chronic renal disease correlates with the magnitude of increases in plasma prouroguanylin concentrations.
Uroguanylin/prouroguanylin levels also increased in the nephrotic syndrome. It may be concluded that uroguanylin/prouroguanylin is cleared from the circulation by the kidney and that reduced functioning renal mass and decreased glomerular filtration rates (GFR) lead to substantial increases in the concentrations of these peptides in serum and plasma. Circulating forms of uroguanylin and prouroguanylin are thought to be a major source of the urinary forms of biologically active uroguanylin. Both of these peptides can enter renal tubules by glomerular filtration. Prouroguanylin in the tubular lumen is than converted to active uroguanylin by tubular endoproteases because prouroguanylin is not detected in the urine.
Studies of pathogenesis of colorectal cancer demonstrate that prouroguanylin may serve as marker of colon tumors in the body. Recent experiments also refer to possibility of prouroguanylin to play a significant role at diagnostic and treatment of heart diseases.
Areas of investigation: Renal disease, Heart failure, Oncology